Literature DB >> 6502941

Effects of L-carnitine on exercise tolerance in patients with stable angina pectoris.

T Kamikawa, Y Suzuki, A Kobayashi, H Hayashi, Y Masumura, K Nishihara, M Abe, N Yamazaki.   

Abstract

The effects of L-carnitine (900 mg, p.o. daily) on exercise performance were studied in 12 patients with stable effort angina using a multistage treadmill exercise test. Exercise tests were performed at the end of the placebo period and after 4 and 12 weeks of carnitine therapy. While 12 patients experienced angina during treadmill tests in the placebo period, 2 patients were free of angina after treatment with carnitine. The mean exercise time was 11.4 +/- 0.7 min (mean +/- SE) in the placebo period. This increased significantly to 12.2 +/- 0.5 min (p less than 0.05) after 4 weeks and 12.8 +/- 0.5 min (p less than 0.01) after 12 weeks of treatment with carnitine. The time required for 1 mm ST depression to occur was 6.4 +/- 0.9 min in the placebo period. This increased significantly to 7.6 +/- 0.9 min (p less than 0.01) after 4 weeks and 8.8 +/- 1.0 min after 12 weeks of treatment with carnitine. There was significantly less ST segment depression during the same exercise load after 12 weeks of treatment as compared with that in the placebo period (p less than 0.05). The heart rate and the pressure rate product at the same work load showed no significant difference among the 3 testing periods. The results of this study suggest that L-carnitine may improve exercise tolerance in patients with effort angina.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502941     DOI: 10.1536/ihj.25.587

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  6 in total

1.  Protective effects of propionyl-L-carnitine during ischemia and reperfusion.

Authors:  A Shug; D Paulson; R Subramanian; V Regitz
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

2.  Delineation of the influence of propionylcarnitine on the accumulation of long-chain acylcarnitines and electrophysiologic derangements evoked by hypoxia in canine myocardium.

Authors:  K A Yamada; D J Dobmeyer; E M Kanter; S G Priori; P B Corr
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

3.  L-carnitine reduces malondialdehyde concentrations in isolated rat hearts in dependence on perfusion conditions.

Authors:  H Löster; U Böhm
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

4.  Lack of correlation between the antiarrhythmic effect of L-propionylcarnitine on reoxygenation-induced arrhythmias and its electrophysiological properties.

Authors:  M Barbieri; P U Carbonin; E Cerbai; G Gambassi; P Lo Giudice; I Masini; A Mugelli; M Pahor
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

Review 5.  l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism.

Authors:  K L Goa; R N Brogden
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

6.  Propionyl carnitine in stable effort angina.

Authors:  A Cherchi; C Lai; E Onnis; E Orani; R Pirisi; M R Pisano; A Soro; M Corsi
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.